Home

Articles from XOMA Royalty Corporation; LAVA Therapeutics N.V.

XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement
- Amendment includes finalized cash amount and updated CVR terms for tender offer
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
XOMA Royalty adds milestone and royalty economics associated with two partnered assets